Table 2 Data at randomization for simulation 1A
From: Preventing false discovery of heterogeneous treatment effect subgroups in randomized trials
Single agent | Combination | ASD | |
|---|---|---|---|
n = 100 | n = 100 | ||
Age (years) | 65.0 (±5.8) | 64.9 (±5.0) | 0.01 |
Stage 4 | |||
No | 4 (4.0%) | 1 (1.0%) | 0.19 |
Yes | 96 (96.0%) | 99 (99.0%) | 0.19 |
Site | |||
Visceral | 53 (53.0%) | 49 (49.0%) | 0.08 |
Bone only | 13 (13.0%) | 13 (13.0%) | 0 |
Other | 34 (34.0%) | 38 (38.0%) | 0.08 |
Previous treatment | |||
None | 56 (56.0%) | 52 (52.0%) | 0.08 |
Chemo only | 17 (17.0%) | 19 (19.0%) | 0.05 |
Hormonal only | 16 (16.0%) | 19 (19.0%) | 0.08 |
Chemo + hormonal | 11 (11.0%) | 10 (10.0%) | 0.03 |
ECOG score | |||
0 | 45 (45.0%) | 37 (37.0%) | 0.16 |
1 | 55 (55.0%) | 63 (63.0%) | 0.16 |
Disease free > 12 months adjuvant to recurrence | |||
No | 65 (65.0%) | 62 (62.0%) | 0.06 |
Yes | 35 (35.0%) | 38 (38.0%) | 0.06 |